Interestingly, BI-5756 dose-dependently decreased the frequencies of CD4 and CD8 double-positive (DP) cells, which are known to be highly potent inducers of GvHD by recognizing antigens presented on both major histocompatibility complex (MHC) classes I and II (Figure 1F). Here, CD8A is linked to graft versus host disease.